0
0
5/23/23 at 12:00pm
Organization
FDA.gov
Author
Office of the Commissioner
30 words
0
Comments
The U.S. Food and Drug Administration approved Brixadi to treat moderate to severe opioid use disorder (OUD).
You are the first to view
https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder
Create an account
or login to join the discussion